Zobrazeno 1 - 10
of 117
pro vyhledávání: ''
Autor:
Gwyn T. Williams, Carlos Caldas, Mirna Mourtada-Maarabouni, Andrew R. Green, Mark R. Pickard, Ian O. Ellis, Vanessa L. Hedge
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: Programmed cell death through apoptosis plays an essential role in the hormone-regulated physiological turnover of mammary tissue. Failure of this active gene-dependent process is central both to the development of breast cancer and to
Publikováno v:
Breast Cancer Research
Introduction Mammographic density is a strong, independent risk factor for breast cancer. A critical unanswered question is whether cancers tend to arise in mammographically dense tissue (i.e. are densities directly related to risk or are they simply
Autor:
Jinbo Chen, Michael Kalos, Joshua Bauml, Angela DeMichele, Susan Q. Li, Jun J. Mao, Jean D. Boyer, Lu Chen
Publikováno v:
Breast Cancer Research : BCR
Introduction Arthralgia is a common toxicity among women taking aromatase inhibitors (AIs) and can lead to premature discontinuation of therapy. We evaluated the association between arthralgia, co-morbid fatigue and/or insomnia, and inflammatory biom
Autor:
Janet R. Daling, Danielle M. Friedrichsen, Elaine A. Ostrander, Kathleen E. Malone, David R. Doody
Publikováno v:
Breast Cancer Research
Introduction The cell-cycle checkpoint kinase (CHEK)2 protein truncating mutation 1100delC has been associated with increased risk for breast or prostate cancer. Multiple studies have found an elevated frequency of the 1100delC variant in specific st
Autor:
Stephanie A. Kennedy, Jennifer Gallagher, Lee G. Wilke, Marlee K. Junker, Nimmi Ramanujam, Torre Michelle Bydlon, Joseph Geradts, J. Quincy Brown, William T. Barry
Publikováno v:
Breast Cancer Research : BCR
Introduction Residual cancer following breast conserving surgery increases the risk of local recurrence and mortality. Margin assessment presents an unmet clinical need. Breast tissue is markedly heterogeneous, which makes distinguishing small foci o
Publikováno v:
Breast Cancer Research : BCR
Introduction Proteasome inhibition provides an attractive approach to cancer therapy and may have application in the treatment of breast cancer. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib
Autor:
Laurence N. Kolonel, Song-Yi Park, Melissa A. Little, Shannon M. Conroy, Gertraud Maskarinec, Ian Pagano
Publikováno v:
Breast Cancer Research : BCR
Introduction Mammographic density, a strong predictor for breast cancer incidence, may also worsen prognosis in women with breast cancer. This prospective analysis explored the effect of prediagnostic mammographic density among 607 breast cancer case
Autor:
David Van Den Berg, Malcolm C. Pike, Yuri R. Parisky, Wendy J. Mack, Christopher A. Haiman, Sue A. Ingles, Sarah J. Lord, Wei Wang, Giske Ursin, Howard N. Hodis
Publikováno v:
Breast Cancer Research
Introduction Mammographic density is a strong independent risk factor for breast cancer, and can be modified by hormonal exposures. Identifying genetic variants that determine increases in mammographic density in hormone users may be important in und
Autor:
Mårten Fernö, Pär-Ola Bendahl, Åke Borg, Lao H. Saal, Cecilia Hegardt, Dorthe Grabau, Gabriella Honeth, Kristina Lövgren, Markus Ringnér, Sofia K. Gruvberger-Saal
Publikováno v:
Breast Cancer Research. 10(3)
Human breast tumors are heterogeneous and consist of phenotypically diverse cells. Breast cancer cells with a CD44+/CD24- phenotype have been suggested to have tumor-initiating properties with stem cell-like and invasive features, although it is uncl
Autor:
Stuart J. Schnitt, Anne C Deitz, James L. Connolly, Graham A. Colditz, Laura C. Collins, Yineng Fu, Mark Galan, Heather J. Baer, Jonathan Marotti, Laurie Galaburda, Rulla M. Tamimi
Publikováno v:
Breast Cancer Research : BCR
Introduction At least four major categories of invasive breast cancer that are associated with different clinical outcomes have been identified by gene expression profiling: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) and ba